Weighted Gene Co-expression Network Analysis of Gene Modules for the Prognosis of Esophageal Cancer
10.1007/s11596-017-1734-8
- Author:
ZHANG CONG
1
;
SUN QIAN
Author Information
1. Cancer Biology Research Center & Key Laboratory of the Ministry of Education
- Keywords:
esophageal cancer;
The Cancer Genome Atlas;
co-expression network analysis;
weighted gene co-expression network analysis;
enrichment analysis
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2017;37(3):319-325
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal cancer is a common malignant tumor,whose pathogenesis and prognosis factors are not fully understood.This study aimed to discover the gene clusters that have similar functions and can be used to predict the prognosis of esophageal cancer.The matched microarray and RNA sequencing data of 185 patients with esophageal cancer were downloaded from The Cancer Genome Atlas (TCGA),and gene co-expression networks were built without distinguishing between squamous carcinoma and adenocarcinoma.The result showed that 12 modules were associated with one or more survival data such as recurrence status,recurrence time,vital status or vital time.Furthemaore,survival analysis showed that 5 out of the 12 modules were related to progression-free survival (PFS) or overall survival (OS).As the most important module,the midnight blue module with 82 genes was related to PFS,apart from the patient age,tumor grade,primary treatment success,and duration of smoking and tumor histological type.Gene ontology enrichment analysis revealed that "glycoprotein binding" was the top enriched function of midnight blue module genes.Additionally,the blue module was the exclusive gene clusters related to OS.Platelet activating factor receptor (PTAFR) and feline Gardner-Rasheed (FGR) were the top hub genes in both modeling datasets and the STRING protein interaction database.In conclusion,our study provides novel insights into the prognosis-associated genes and screens out candidate biomarkers for esophageal cancer.
